Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis

被引：30

作者：

Laprise, Jean-Francois ^{[1
]}

Markowitz, Lauri E. ^{[2
]}

Chesson, Harrell W. ^{[2
]}

Drolet, Melanie ^{[1
]}

Brisson, Marc ^{[1
,3
,4
]}

机构：

[1] Univ Laval, CHU Quebec, Ctr Rech, Axe Sante Populat & Prat Optimales Sante, Quebec City, PQ, Canada

[2] Ctr Dis Control & Prevent, Atlanta, GA USA

[3] Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ, Canada

[4] Imperial Coll, Dept Infect Dis Epidemiol, London, England

来源：

JOURNAL OF INFECTIOUS DISEASES | 2016年 / 214卷 / 05期

基金：

加拿大健康研究院;

关键词：

human papillomavirus (HPV); HPV vaccination; cost-effectiveness; transmission-dynamic modeling; HPV VACCINE; LONG-TERM; IMMUNOGENICITY; ADOLESCENTS; EFFICACY; COVERAGE; SAFETY; WOMEN;

D O I：

10.1093/infdis/jiw227

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model to compare the population-level effectiveness and cost-effectiveness of 2- and 3-dose schedules of 9-valent HPV vaccine in the United States. Our model predicts that if 2 doses of 9-valent vaccine protect for a parts per thousand yen20 years, the additional benefits of a 3-dose schedule are small as compared to those of 2-dose schedules, and 2-dose schedules are likely much more cost-efficient than 3-dose schedules.

引用

页码：685 / 688

页数：4

共 15 条

[1] Health and Economic Impact of Switching From a 4-Valent to a 9-Valent HPV Vaccination Program in the United States [J].

Brisson, Marc ;

Laprise, Jean-Francois ;

Chesson, Harrell W. ;

Drolet, Melanie ;

Malagon, Talia ;

Boily, Marie-Claude ;

Markowitz, Lauri E. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (01)

[2] Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial [J].

Dobson, Simon R. M. ;

McNeil, Shelly ;

Dionne, Marc ;

Dawar, Meena ;

Ogilvie, Gina ;

Krajden, Mel ;

Sauvageau, Chantal ;

Scheifele, David W. ;

Kollmann, Tobias R. ;

Halperin, Scott A. ;

Langley, Joanne M. ;

Bettinger, Julie A. ;

Singer, Joel ;

Money, Deborah ;

Miller, Dianne ;

Naus, Monika ;

Marra, Fawziah ;

Young, Eric .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (17) :1793-1802

[3] Long-term Study of a Quadrivalent Human Papillomavirus Vaccine [J].

Ferris, Daron ;

Samakoses, Rudiwilai ;

Block, Stan L. ;

Lazcano-Ponce, Eduardo ;

Alberto Restrepo, Jaime ;

Reisinger, Keith S. ;

Mehlsen, Jesper ;

Chatterjee, Archana ;

Iversen, Ole-Erik ;

Sings, Heather L. ;

Shou, Qiong ;

Sausser, Timothy A. ;

Saah, Alfred .

PEDIATRICS, 2014, 134 (03) :E657-E665

[4] Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model [J].

Jit, Mark ;

Brisson, Marc ;

Laprise, Jean-Francois ;

Choi, Yoon Hong .

BMJ-BRITISH MEDICAL JOURNAL, 2015, 350

[5] A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women [J].

Joura, E. A. ;

Giuliano, A. R. ;

Iversen, O-E ;

Bouchard, C. ;

Mao, C. ;

Mehlsen, J. ;

Moreira, E. D., Jr. ;

Ngan, Y. ;

Petersen, L. K. ;

Lazcano-Ponce, E. ;

Pitisuttithum, P. ;

Restrepo, J. A. ;

Stuart, G. ;

Woelber, L. ;

Yang, Y. C. ;

Cuzick, J. ;

Garland, S. M. ;

Huh, W. ;

Kjaer, S. K. ;

Bautista, O. M. ;

Chan, I. S. F. ;

Chen, J. ;

Gesser, R. ;

Moeller, E. ;

Ritter, M. ;

Vuocolo, S. ;

Luxembourg, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) :711-723

[6] Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials [J].

Kreimer, Aimee R. ;

Struyf, Frank ;

Del Rosario-Raymundo, Mora Rowena ;

Hildeshim, Allan ;

Skinner, S. Rachel ;

Wacholder, Sholom ;

Garland, Suzanne M. ;

Herrero, Rolando ;

David, Marfe-Pierre ;

Mfeeler, Cosette M. .

LANCET ONCOLOGY, 2015, 16 (07) :775-786

[7] Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study [J].

Laprise, Jean-Francois ;

Drolet, Melanie ;

Boily, Marie-Claude ;

Jit, Mark ;

Sauvageau, Chantal ;

Franco, Eduardo L. ;

Lemieux-Mellouki, Philippe ;

Malagon, Talia ;

Brisson, Marc .

VACCINE, 2014, 32 (44) :5845-5853

[8]

Luxembourg A., 2016, M ADV COMM IMM PRACT

[9] 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors [J].

Massad, L. Stewart ;

Einstein, Mark H. ;

Huh, Warner K. ;

Katki, Hormuzd A. ;

Kinney, Walter K. ;

Schiffman, Mark ;

Solomon, Diane ;

Wentzensen, Nicolas ;

Lawson, Herschel W. .

OBSTETRICS AND GYNECOLOGY, 2013, 121 (04) :829-846

[10] Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination [J].

Naud, Paulo S. ;

Roteli-Martins, Cecilia M. ;

De Carvalho, Newton S. ;

Teixeira, Julio C. ;

de Borba, Paola C. ;

Sanchez, Nervo ;

Zahaf, Toufik ;

Catteau, Gregory ;

Geeraerts, Brecht ;

Descamps, Dominique .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) :2147-2162

← 1 2 →